Vivos Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Vivos Therapeutics Inc (VVOS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Vivos Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 21M vs 5,743M combined for its competitors (0.4% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-2.5% annualized vs trailing 12 months), vs holding steady (+1.9%) for its tracked peer group.
- Growth: Vivos Therapeutics Inc generated 65.7% revenue growth year over year in Q2 2026, vs 9.2% for its competitors combined.
- Profitability: Its -107.2% net margin compares with 26.2% for the peer group.
- Scale: Vivos Therapeutics Inc ranks #192 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
- Peer revenue share: Vivos Therapeutics Inc accounted for 0.4% of combined revenue among its tracked peer group, up from 0.2% a year earlier.
- Peer differentiation: Revenue per employee of $0.08M compares with $0.37M for the peer group (0.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
VVOS Sales vs. its Competitors, Q2 2026
Vivos Therapeutics Inc reported revenue growth of 65.69 % year on year in Q2 2026, above its competitors' combined revenue growth of 9.22 %.
With a net margin of -107.18 %, Vivos Therapeutics Inc reported lower profitability than its competitors (26.20 %).
Vivos Therapeutics Inc generated 0.35 % of the combined sales of its peer group, up from 0.23 % a year earlier.
API endpoints for this dataset
Vivos Therapeutics Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Vivos Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Vivos Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Vivos Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Vivos Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.4% year over year, combined, vs 65.7% for Vivos Therapeutics Inc. Vivos Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Vivos Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Vivos Therapeutics Inc | - | Yes | Yes | No |
| Competitors combined (5) | ||||
| High-Confidence Competitors (1) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
VVOS Stock Performance relative to its Competitors
VVOS Stock Performance relative to High-Confidence Competitors
VVOS Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Huntsman Corporation | 282.9% | Outperformed |
| 2 | Koninklijke Philips Nv | 282.9% | Outperformed |
| 3 | Resmed Inc | 282.9% | Outperformed |
| 4 | Vivos Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Vivos Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Vivos Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Vivos Therapeutics Inc |
1.69 | 21.14 |
 Resmed Inc |
33,807.71 | 5,743.16 |
 Koninklijke Philips Nv |
29,635.47 | 20,163.51 |
 Huntsman Corporation |
1,650.42 | 5,693.00 |
 Vivos Inc |
20.34 | 0.08 |
 Sleep Number Corporation |
0.80 | 1,337.03 |
| SUBTOTAL | 65,116.44 | 32,957.91 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Vivos Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Vivos Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Vivos Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Inspire Medical | Company report | 85% |
| Vivos Inc | Company report | 85% |
| Huntsman Corporation | Company report | 85% |
| Koninklijke Philips Nv | Company report | 85% |
| Resmed Inc | Company report | 85% |
| Sleep Number Corporation | Company report | 85% |
Company report basis, confidence, active dates and source counts for Vivos Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Vivos Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Resmed Inc | Devices 49.96 % |
| Huntsman Corporation | Polyurethanes 58.14 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Vivos Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Vivos Therapeutics Inc | 2 | 78,862 | -95,623 |
| Resmed Inc | 33,808 | 505,116 | 140,120 |
| Koninklijke Philips Nv | 29,635 | 294,706 | 14,823 |
| Huntsman Corporation | 1,650 | 948,833 | -46,500 |
| Vivos Inc | 20 | 38,850 | -1,708,083 |
| Sleep Number Corporation | 1 | 426,757 | -55,413 |
| PEERS TOTAL | 65,115 | 370,392 | 24,193 |
Vivos Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Resmed Inc | Combined Europe Asia and other markets 31.05 % |
| Huntsman Corporation | Asia Pacific 33.59 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Vivos Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Vivos Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Vivos Therapeutics Inc ranks #192 of 218 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 607, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 164,558 | 13.47 % |
| 2 | Medtronic Plc | 132,095 | 10.81 % |
| 3 | Stryker Corp | 125,732 | 10.29 % |
| 4 | 3m Company | 98,540 | 8.06 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Medline Inc | 1,234 | 5.2% |
| 10 | Resmed Inc | 1,234 | 5.2% |
| 192 | Vivos Therapeutics Inc | 2 | 0.00 % |
Market cap and industry share for the rest of Vivos Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Vivos Therapeutics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 187 | Escalon Medical Corp | 3 | - |
| 188 | Fuse Medical Inc | 2 | - |
| 189 | Aethlon Medical Inc | 2 | 30.75 % |
| 190 | Valion Bio Inc | 2 | -76.07 % |
| 191 | Icecure Medical Ltd | 1,234 | 12.3% |
| 192 | Vivos Therapeutics Inc | 2 | -95.91 % |
| 193 | Envue Medical Inc | 1,234 | 12.3% |
| 194 | Invo Fertility Inc | 1,234 | 12.3% |
| 195 | Vycor Medical Inc | 1,234 | 12.3% |
| 196 | Adagio Medical Holdings inc | 1,234 | 12.3% |
| 197 | Co diagnostics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Vivos Therapeutics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Vivos Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 61.20 % | 46.20 % (avg) | +15.0 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.66 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 33.44 % | 7.13 % (avg) | +26.3 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Vivos Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 36.9x | - |
| EV / EBITDA | - | 17.8x | - |
| P/B | -13.0x | 4.6x | -17.6x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | -282.85 % | -6.78 % (avg) | -276.07 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Vivos Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | -17.18 % | 13.17 % | 10.14 % |
| Operating Margin | - | -156.21 % | - | -74.38 % | - |
| Return on Invested Capital | - | -90.35 % | -226.23 % | -79.78 % | -129.39 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Vivos Therapeutics Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Vivos Therapeutics Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.9% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Vivos Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 607 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 33.44 % vs industry average 7.13 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Vivos Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Vivos Therapeutics Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Vivos Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Vivos Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-2.5% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of competitors (40.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Vivos Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Vivos Therapeutics Inc | 0.14 | 0.30 | - |
| Resmed Inc | 1.05 | 3.03 | 0.10 |
| Koninklijke Philips Nv | 0.37 | 1.32 | 0.73 |
| Huntsman Corporation | 0.26 | 1.34 | 0.68 |
| Vivos Inc | 17.94 | 18.69 | - |
| Sleep Number Corporation | 0.00 | 0.18 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Vivos Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Vivos Therapeutics Inc | Q2 2026 | +65.7 % | - |
| Resmed Inc | Q3 2026 | +8.7 % | +20.0 % |
| Koninklijke Philips Nv | Q4 2025 | +3.4 % | - |
| Huntsman Corporation | Q1 2026 | +0.7 % | - |
| Vivos Inc | Q1 2026 | +34.8 % | - |
| Sleep Number Corporation | Q1 2026 | -18.8 % | - |
| PEERS TOTAL | +3.2 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Vivos Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Vivos Therapeutics Inc | Q2 2026 | +120.0 % | -46.0 % |
| Resmed Inc | Q3 2026 | +5.1 % | +13.4 % |
| Koninklijke Philips Nv | Q4 2025 | +4.6 % | -11.3 % |
| Huntsman Corporation | Q1 2026 | +2.3 % | +5.6 % |
| Vivos Inc | Q1 2026 | +23.0 % | - |
| Sleep Number Corporation | Q1 2026 | -11.8 % | +18.3 % |
Vivos Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Vivos Therapeutics Inc | - | - | - |
| Resmed Inc | 18.67% | 21.10% | 25.50% |
| Koninklijke Philips Nv | 3.21% | 3.86% | 7.86% |
| Huntsman Corporation | - | - | - |
| Vivos Inc | - | - | - |
| Sleep Number Corporation | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Vivos Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Vivos Therapeutics Inc | - | 0.08 |
| Resmed Inc | 21.49 | 5.89 |
| Koninklijke Philips Nv | 33.11 | 1.47 |
| Huntsman Corporation | - | 0.29 |
| Vivos Inc | - | 261.72 |
| Sleep Number Corporation | - | 0.00 |
| PEERS AVERAGE | 30.63 | 1.98 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.